Institutional Ownership
Casi Pharmaceuticals Inc
CUSIP G1933S101ORD SHSCASIFQ1 2026
13D / 13G Filings
27
Schedule 13D/13G on record
Beneficial Filers
10
Distinct reporting persons
Largest Stake
45.4%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
27 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.2% | 1.99M | SEC |
| 2 | Feb 13, 2026 | Foresite Capital Fund Vi LP | 13G/A | 11.0% | 9 | SEC |
| 3 | Feb 10, 2026 | Wei-Wu He, Ph.D. | 13D/A | 45.4% | — | SEC |
| 4 | Jan 29, 2026 | Wei-Wu He, Ph.D. | 13D/A | 34.8% | — | SEC |
| 5 | Jan 20, 2026 | Idg-Accel China Growth Fund III L.P. | 13D/A | 4.8% | — | SEC |
| 6 | Jan 20, 2026 | Sparkle Byte Ltd | 13D/A | 5.0% | — | SEC |
| 7 | Jan 9, 2026 | Wei-Wu He, Ph.D. | 13D/A | 19.1% | — | SEC |
| 8 | Dec 18, 2025 | Wei-Wu He, Ph.D. | 13D/A | 19.1% | — | SEC |
| 9 | Dec 17, 2025 | Panacea Venture Healthcare Fund II, L.P. | 13D/A | 22.5% | — | SEC |
| 10 | Nov 26, 2025 | Chen Zhenfeng | 13G | 11.0% | 2.26M | SEC |
17 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Casi Pharmaceuticals Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Simplex Trading, LLC | 228 | $25 |